Analysts’ Weekly Ratings Updates for Protagonist Therapeutics (PTGX)

Protagonist Therapeutics (NASDAQ: PTGX) recently received a number of ratings updates from brokerages and research firms:

• 3/3/2026 – Protagonist Therapeutics had its price target raised by The Goldman Sachs Group, Inc. from $65.00 to $95.00. They now have a “neutral” rating on the stock.
• 2/26/2026 – Protagonist Therapeutics had its price target raised by TD Cowen from $90.00 to $100.00. They now have a “buy” rating on the stock.
• 2/26/2026 – Protagonist Therapeutics had its price target raised by Barclays PLC from $108.00 to $113.00. They now have an “overweight” rating on the stock.
• 2/26/2026 – Protagonist Therapeutics had its price target raised by Citizens Jmp from $102.00 to $112.00. They now have a “market outperform” rating on the stock.
• 2/17/2026 – Protagonist Therapeutics was downgraded by Weiss Ratings from “hold (c-)” to “sell (d+)”.
• 2/2/2026 – Protagonist Therapeutics had its price target raised by Jefferies Financial Group Inc. from $95.00 to $118.00. They now have a “buy” rating on the stock.
• 1/30/2026 – Protagonist Therapeutics had its price target raised by HC Wainwright from $80.00 to $117.00. They now have a “buy” rating on the stock.

Insider Buying and Selling

In related news, insider Arturo Md Molina sold 5,000 shares of the business’s stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $82.00, for a total transaction of $410,000.00. Following the transaction, the insider owned 84,115 shares in the company, valued at $6,897,430. The trade was a 5.61% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director William D. Waddill sold 20,000 shares of the stock in a transaction on Friday, February 6th. The stock was sold at an average price of $83.68, for a total transaction of $1,673,600.00. Following the transaction, the director directly owned 7,825 shares in the company, valued at approximately $654,796. This represents a 71.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 203,167 shares of company stock worth $16,889,199 over the last ninety days. 4.90% of the stock is owned by company insiders.

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.